DelveInsight launched a new report on Spinocerebellar Ataxias Market Insights, Epidemiology, and Market Forecast-2032.
DelveInsight’s “Spinocerebellar Ataxias Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Spinocerebellar Ataxias , historical and forecasted epidemiology as well as the Spinocerebellar Ataxias market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Spinocerebellar Ataxias Overview
Ataxia is a degenerative condition that affects your nervous system. It involves problems with coordination and movement. Spinocerebellar ataxia (SCA) is a group of inherited brain disorders. It affects your cerebellum, a part of your brain vital to coordination of physical movement, and sometimes your spinal cord. This inherited condition worsens over time and causes specific problems with coordination, usually affecting eyes, hands, legs and mobility, and speech.
To date, more than 40 distinct genetic Spinocerebellar Ataxias have been identified which are classified according to the genetic loci in order of identification. The numbers indicate the order in which experts discovered the associated mutations. SCA1 was the first Spinocerebellar Ataxias described and then further subtypes are identified sequentially. Spinocerebellar Ataxias doesn’t compulsorily mean that it is restricted to the cerebellum and spinal cord. It may involve the other parts of the central nervous system as well, such as pontine nuclei, spinal cord, peripheral nerves, cortex, basal ganglia, etc. SCA6 is restricted to the cerebellum whereas SCA2 spares the cerebellum. The most common type is spinocerebellar ataxia type 3, also known as Machado-Joseph disease.
An inherited gene mutation causes Spinocerebellar Ataxias. Some types of Spinocerebellar Ataxias occur because a segment of DNA abnormally repeats several times (called trinucleotide repeat expansion). The condition is usually inherited in an autosomal dominant fashion. This means that it takes only one copy of the mutated gene from one biological parent to cause the condition. Therefore, when a person with Spinocerebellar Ataxias has children, each child has a 50% chance of inheriting the mutated gene. There are also autosomal recessive spinocerebellar ataxias. In these cases, a person inherits an abnormal gene from both biological parents, who are generally asymptomatic.
Signs and symptoms of Spinocerebellar Ataxias usually appear after age 18 and slowly worsen over several years. Spinocerebellar Ataxias symptoms often include involuntary eye movements, poor hand-eye coordination, problems with balance and coordination, slurred speech, trouble processing and remembering information (learning disabilities), and uncoordinated walking.
Request for free sample copy of the report: https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-market
According to Teive et al. (2019), in the United States, a study of 109 SCA cases with confirmed genetic diagnoses published more than 20 years ago found that the most common subtype was SCA3 detected in 33.9%, followed by both SCA2 and SCA6 in 24.8%, then SCA1 in 9.2%, and SCA7 in 7.3%.Similar figures were confirmed later in a broader 12‐center study of 345 patients in which SCA3 accounted for 40%, followed by SCA2 in 21.7%, SCA6 in 21%, and SCA1 in 17.4%.
The Spinocerebellar Ataxias market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Spinocerebellar Ataxias market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.
This segment gives a thorough detail of the Spinocerebellar Ataxias market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Spinocerebellar Ataxias market in the 7MM is expected to witness a major change in the study period 2019–2032.
Spinocerebellar Ataxia Key pharma players involved:
• Seelos Therapeutics
• VICO Therapeutics
• Wave Life Sciences
• Biohaven Pharmaceuticals
• Steminent Biotherapeutics
Click here and get access to a free sample copy of the Spinocerebellar Ataxia market report 2032.
Table of contents
1 Key Insight
2 Executive Summary of Spinocerebellar Ataxia
3 Spinocerebellar Ataxia Market Overview at a Glance
4 Disease Background and Overview: Spinocerebellar Ataxia
5 Case Reports
6 Spinocerebellar Ataxia Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Spinocerebellar Ataxia Treatment and Medical Practices
11 Unmet needs
12 Spinocerebellar Ataxia Marketed Drugs
13 Spinocerebellar Ataxia Emerging Drugs
14 Spinocerebellar Ataxia 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Spinocerebellar Ataxia Market Drivers
19 Spinocerebellar Ataxia Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
23 DelveInsight Capabilities
25 About DelveInsight
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States